Abstract

Patients diagnosed with Glioblastoma multiforme (GBM) only survive a median time of sixteen (16) months through extensive neurosurgery and chemotherapy along with radiation therapy. Research has demonstrated that within a timeframe of five (5) days HNSCs are able to migrate next to the brain tumors in mice. Therefore, it may be concluded that the tumor itself along with surrounding tissue should contain an abundant amount of HNSCs. Integrating this knowledge, a novel GBM therapy may be devised. The long range goal is to remove tumors from GBM patients, isolate the patients Human Neural Stem Cells (HNSCs), transfect them with the PEX gene within a mammalian expression vector and then transplant the patients original HNSCs back into the brain. PEX is part of the C-terminal fragment of MMP2 metalloproteinase shown to prevent "normal biding to alpha-V/bet a-3 and disrupts angiogenesis and tumor growth". The central hypothesis is that after transfection of the patients HNSCs of t

Document Type

Patent

Patent Number

US 8,518,698

Application Serial Number

12/168,485

Issue Date

8-27-2013

Current Assignee

UCFRF

Assignee at Issuance

UCFRF

College

Burnett School of Biomedical Sciences

Department

Biomolecular Science Center

Allowance Date

12-19-2012

Filing Date

7-7-2008

Assignee at Filing

UCFRF

Filing Type

Nonprovisional Application Record

Donated

no

Download Patent

Share

COinS